HUTCHMED (China) Limited and Travere Therapeutics, Inc.: A Detailed Gross Profit Analysis

Pharma Giants: A Decade of Gross Profit Evolution

__timestampHUTCHMED (China) LimitedTravere Therapeutics, Inc.
Wednesday, January 1, 20141976400027632226
Thursday, January 1, 20156742600097707000
Friday, January 1, 201659752000129037000
Sunday, January 1, 201765383000151332000
Monday, January 1, 201870165000158719000
Tuesday, January 1, 201944738000170104000
Wednesday, January 1, 202039457000192195000
Friday, January 1, 202197894000220706000
Saturday, January 1, 2022115306000204426000
Sunday, January 1, 2023453552000133788000
Loading chart...

Unlocking the unknown

A Comparative Analysis of Gross Profit Trends

In the dynamic world of pharmaceuticals, understanding financial trends is crucial. This analysis delves into the gross profit trajectories of HUTCHMED (China) Limited and Travere Therapeutics, Inc. over the past decade. From 2014 to 2023, HUTCHMED's gross profit surged by an impressive 2,200%, peaking in 2023. In contrast, Travere Therapeutics experienced a more modest growth of approximately 384% during the same period, with its highest profit recorded in 2021.

Key Insights

  • HUTCHMED's Growth: The company saw a significant leap in 2023, marking a pivotal year with a gross profit increase of over 290% from the previous year.
  • Travere's Stability: Despite fluctuations, Travere maintained a steady upward trend, with a notable peak in 2021.

These insights highlight the contrasting growth strategies and market responses of these two industry players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025